Cai Jing Wang·2025-10-09 03:04Core Insights - 诺诚健华 and Zenas BioPharma have entered into a licensing agreement for the global development and commercialization rights of 奥布替尼 in multiple sclerosis and other non-oncological indications [1][2] - Zenas will pay up to $100 million in upfront and milestone payments, with total transaction value exceeding $2 billion [1][2] - 奥布替尼 is a potential best-in-class oral BTK inhibitor with strong CNS penetration, currently undergoing clinical trials for multiple sclerosis [2][3] Group 1 - Zenas will receive exclusive global rights for 奥布替尼 in multiple sclerosis and non-oncological indications outside Greater China and Southeast Asia [2] - 诺诚健华 retains global rights for 奥布替尼 in oncology and in non-oncological indications within Greater China and Southeast Asia [2] - Zenas also gains rights to a novel oral IL-17 AA/AF inhibitor and a CNS-penetrant oral TYK2 inhibitor [1][2] Group 2 - A Phase III clinical trial has been initiated to evaluate the safety and efficacy of 奥布替尼 in primary progressive multiple sclerosis patients [2] - Zenas plans to start a second Phase III trial for secondary progressive multiple sclerosis in Q1 2026 [2] - In a previous Phase II trial, 奥布替尼 significantly reduced the number of new Gd+ T1 MRI brain lesions compared to placebo, demonstrating sustained reduction in inflammatory activity [3]